Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression

Abstract Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal adenocarcinoma development. Materials and methods. Pathomorphological and immunohistochemical studies of surgical material of colorectal adenocarcinom...

Full description

Bibliographic Details
Main Author: M. A. Shyshkin
Format: Article
Language:English
Published: Zaporozhye State Medical University 2019-09-01
Series:Patologìâ
Subjects:
Online Access:http://pat.zsmu.edu.ua/article/view/177075/178396
_version_ 1818787031896031232
author M. A. Shyshkin
author_facet M. A. Shyshkin
author_sort M. A. Shyshkin
collection DOAJ
description Abstract Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal adenocarcinoma development. Materials and methods. Pathomorphological and immunohistochemical studies of surgical material of colorectal adenocarcinoma (CRA) from 40 patients (I, II, III and IV stages, 10 cases in each group) were conducted. Results. There is a tendency to increasing expression of VEGF-A and VEGFR-2 during the CRA progression from I to IV stage (VEGF-A 37.80 (30.22; 56.89) CUOD on I stage, 88.50 (63.00 ; 115.00) CUOD on II stage, 79.34 (63.14; 84.99) CUOD on III stage, 84.69 (80.66; 110.28) CUOD on IV stage; VEGFR-2 – 52.75 (39.14; 70.22) CUOD on I stage, 82.71 (63.14; 111.19) CUOD on II stage, 104.17 (96.04; 111.02) CUOD on III stage, 99.91 (86.15; 120.29) CUOD on IV stage). The expression indices of these markers correlate in CRA stages I, II and III (r = 0.95, r = 0.69, r = 0.85). It is established that VEGFR-1 is not expressed in unchanged mucous membrane of the large intestine, as well as in samples of CRA stage I. On subsequent II, III and IV stages of CRA progresson the marker is expressed by stromal cells, but there is an absence of statistically significant difference between the expression indices. There are no correlations between expression indices of VEGFR-1 and other studied markers. The microvascular density assessed by CD34 expression is not significantly different on each of CRA progression stages. There are direct correlations between microvascular density and VEGF-A expression (r = 0.70), and VEGFR-2 expression (r = 0.69) in CRA III stage, microvascular density and VEGF-A expression in CRA IV stage (r = 0.69). Conclusions. Expression of VEGF-A and VEGFR-2 increases with the progression of colorectal adenocarcinoma from stage I to stage IV, with a maximum “jump” of the expression levels from stage I to stage II of colorectal adenocarcinoma, which may be due to abnormally increasing KRAS activity.
first_indexed 2024-12-18T14:01:19Z
format Article
id doaj.art-e5434800cd2346e4afa6e90498ac68ea
institution Directory Open Access Journal
issn 2306-8027
2310-1237
language English
last_indexed 2024-12-18T14:01:19Z
publishDate 2019-09-01
publisher Zaporozhye State Medical University
record_format Article
series Patologìâ
spelling doaj.art-e5434800cd2346e4afa6e90498ac68ea2022-12-21T21:05:19ZengZaporozhye State Medical UniversityPatologìâ2306-80272310-12372019-09-0116214815410.14739/2310-1237.2019.2.177075Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progressionM. A. ShyshkinAbstract Aim – to study VEGF-A, VEGFR-1, VEGFR-2 and CD34 immunohistochemical expression on the I, II, III, IV stages (pTNM) of colorectal adenocarcinoma development. Materials and methods. Pathomorphological and immunohistochemical studies of surgical material of colorectal adenocarcinoma (CRA) from 40 patients (I, II, III and IV stages, 10 cases in each group) were conducted. Results. There is a tendency to increasing expression of VEGF-A and VEGFR-2 during the CRA progression from I to IV stage (VEGF-A 37.80 (30.22; 56.89) CUOD on I stage, 88.50 (63.00 ; 115.00) CUOD on II stage, 79.34 (63.14; 84.99) CUOD on III stage, 84.69 (80.66; 110.28) CUOD on IV stage; VEGFR-2 – 52.75 (39.14; 70.22) CUOD on I stage, 82.71 (63.14; 111.19) CUOD on II stage, 104.17 (96.04; 111.02) CUOD on III stage, 99.91 (86.15; 120.29) CUOD on IV stage). The expression indices of these markers correlate in CRA stages I, II and III (r = 0.95, r = 0.69, r = 0.85). It is established that VEGFR-1 is not expressed in unchanged mucous membrane of the large intestine, as well as in samples of CRA stage I. On subsequent II, III and IV stages of CRA progresson the marker is expressed by stromal cells, but there is an absence of statistically significant difference between the expression indices. There are no correlations between expression indices of VEGFR-1 and other studied markers. The microvascular density assessed by CD34 expression is not significantly different on each of CRA progression stages. There are direct correlations between microvascular density and VEGF-A expression (r = 0.70), and VEGFR-2 expression (r = 0.69) in CRA III stage, microvascular density and VEGF-A expression in CRA IV stage (r = 0.69). Conclusions. Expression of VEGF-A and VEGFR-2 increases with the progression of colorectal adenocarcinoma from stage I to stage IV, with a maximum “jump” of the expression levels from stage I to stage II of colorectal adenocarcinoma, which may be due to abnormally increasing KRAS activity.http://pat.zsmu.edu.ua/article/view/177075/178396colorectal cancer; neovascularization; pathologic; Vascular Endothelial Growth Factor AVascular Endothelial Growth Factor Receptor-1Vascular Endothelial Growth Factor Receptor-2CD34 Antigen
spellingShingle M. A. Shyshkin
Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
Patologìâ
colorectal cancer; neovascularization; pathologic; Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
CD34 Antigen
title Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
title_full Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
title_fullStr Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
title_full_unstemmed Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
title_short Immunohistochemical study of VEGF-A, VEGFR-1, VEGFR-2 and CD34 expression in сolorectal adenocarcinoma progression
title_sort immunohistochemical study of vegf a vegfr 1 vegfr 2 and cd34 expression in сolorectal adenocarcinoma progression
topic colorectal cancer; neovascularization; pathologic; Vascular Endothelial Growth Factor A
Vascular Endothelial Growth Factor Receptor-1
Vascular Endothelial Growth Factor Receptor-2
CD34 Antigen
url http://pat.zsmu.edu.ua/article/view/177075/178396
work_keys_str_mv AT mashyshkin immunohistochemicalstudyofvegfavegfr1vegfr2andcd34expressioninsolorectaladenocarcinomaprogression